Results from the longest global Phase 3 open-label extension trial in this age group in asthma show sustained improvement in lung function, low rate of asthma attacks and a consistent safety profile for up to two years
https://finance.yahoo.com/news/breaking-dupixent-dupilumab-data-ers-112900305.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.